Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers
Completed
Bausch & Lomb Incorporated
Phase 1
2013-07-01
The objective of this study is to evaluate the effect of latanoprostene bunod dosed once
daily (QD) in reducing intraocular pressure (IOP) measured over a 24-hour period in healthy
subjects.
Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity
Completed
Bausch & Lomb Incorporated
N/A
2018-12-03
The purpose of this research study is to compare the effect of Latanoprostene Bunod and
Timolol on eye pressure and blood vessels of the back of the eye.
Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity
Completed
University of California, San Diego
N/A
2018-12-03
The purpose of this research study is to compare the effect of Latanoprostene Bunod and
Timolol on eye pressure and blood vessels of the back of the eye.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
